Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 9;14(12):2031.
doi: 10.3390/foods14122031.

In Situ Cross-Linked Porous Starch Microencapsulation Enhances the Colonization of Lactobacillus In Vivo

Affiliations

In Situ Cross-Linked Porous Starch Microencapsulation Enhances the Colonization of Lactobacillus In Vivo

Xiaojun Zhang et al. Foods. .

Abstract

In this study, we developed novel porous starch (PS)/Lactobacillus (LS) microcapsules via in situ cross-linking with sodium trimetaphosphate (STMP), using Lactobacillus johnsonii (LJ), Lactobacillus acidophilus (LA), and Lactobacillus rhamnosus GG (LGG) as representative strains. Scanning electron microscopy (SEM) revealed that the cross-linked microcapsules (designated as PS/LS-CL: PS/LJ-CL, PS/LA-CL, PS/LGG-CL) formed aggregated structures with denser microarchitecture compared to uncross-linked porous starch/Lactobacillus microcapsules (designated as PS/LS: PS/LJ, PS/LA, PS/LGG). The encapsulation efficiencies of PS/LJ-CL, PS/LA-CL, and PS/LGG-CL (79.56%, 78.49%, and 55.96%, respectively) significantly surpassed those of their uncross-linked counterparts (67.92%, 58.68%, and 47.71%, p < 0.05). In addition, the cross-linked porous starch microcapsules improved the survival rate of Lactobacillus during simulated gastrointestinal digestion and long-time storage. Importantly, the oral gavage of PS/LS-CL, PS/LA-CL, and PS/LGG-CL significantly increased the amount of Lactobacillus. The colonization efficiency of all the tested Lactobacillus in mice was detected by both gradient dilution plate counting and quantitative real-time PCR (qRT-PCR). These findings indicate the potential function of the in situ cross-linked porous starch microcapsules as a robust delivery system to enhance the colonization of probiotics in vivo.

Keywords: delivery system; encapsulation efficiency; oral gavage; simulated digestion; survival rate.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Schematic diagrams for the preparation of PS/LS and PS/LS-CL.
Figure 2
Figure 2
Electron micrographs of (A) porous starch (PS), (B) Lactobacillus johnsonii (LJ), (C) Lactobacillus acidophilus (LA), (D) Lactobacillus rhamnosus GG (LGG), (E) LJ encapsulated in PS (PS/LJ), (F) LA encapsulated in PS (PS/LA), (G) LGG encapsulated in PS (PS/LGG), (H) LJ encapsulated in PS via in situ cross-linking (PS/LJ-CL), (I) LA encapsulated in PS via in situ cross-linking (PS/LA-CL), (J) LGG encapsulated in PS via in situ cross-linking (PS/LGG-CL). The regions marked by red circles indicate Lactobacillus adhesion on the surface of porous starch or penetration into its micropores.
Figure 3
Figure 3
Survival Lactobacillus in PS/LS-CL and PS/LS during storage time (4 °C, 60% RH).
Figure 4
Figure 4
In vivo colonization detection in mouse colon after 7-day oral gavage. (A) BALB/c mice (6–8 weeks old) received daily oral gavage for 7 consecutive days, and their fresh fecal samples were aseptically collected 48 h after the final administration, immediately snap-frozen in liquid nitrogen, and stored at −80 °C until analysis. The control group: daily oral gavage of 200 μL 0.01 M phosphate-buffered saline (PBS, pH 7.4); LS groups (LJ, LA, LGG) daily oral gavage of 200 μL PBS containing free Lactobacillus cells (1 × 108 CFU); PS/LS-CL groups (PS/LJ-CL, PS/LA-CL, PS/LGG-CL): daily oral gavage of 200 μL PBS containing Lactobacillus cells (1 × 108 CFU). (BD) the abundance of LJ, LA, and LGG in fecal samples via gradient dilution plate counting. (EG) the abundance of LJ, LA, and LGG in fecal samples via qRT-PCR. ns: not significant; * p < 0.05, ** p < 0.01, *** p < 0.001.

References

    1. Chen Y., Gao H., Zhao J., Ross R.P., Stanton C., Zhang H., Chen W., Yang B. Exploiting lactic acid bacteria for inflammatory bowel disease: A recent update. Trends Food Sci. Technol. 2023;138:126–140. doi: 10.1016/j.tifs.2023.06.007. - DOI
    1. Wang T., Shi Z., Ren H., Xu M., Lu J., Yang F., Ye C., Wu K., Chen M., Xu X., et al. Divergent age-associated and metabolism-associated gut microbiome signatures modulate cardiovascular disease risk. Nat. Med. 2024;30:1722–1731. doi: 10.1038/s41591-024-03038-y. - DOI - PubMed
    1. Lei G., Khan A., Budryn G., Grzelczyk J. Probiotic products from laboratory to commercialization. Trends Food Sci. Technol. 2025;155:104807. doi: 10.1016/j.tifs.2024.104807. - DOI
    1. Mansa F., Nii A., Simon G. Assessing gastric viability of probiotics: Real testing in real human gastric fluid. Health Sci. Investig. J. 2024;6:808–813. doi: 10.46829/hsijournal.2024.7.6.1.808-813. - DOI
    1. Yu H., Kong Q., Wang M., Han Z., Xu J. Improved viability of probiotics by encapsulation in chickpea protein matrix during simulated gastrointestinal digestion by succinylated modification. Int. J. Biol. Macromol. 2024;260:129614. doi: 10.1016/j.ijbiomac.2024.129614. - DOI - PubMed

LinkOut - more resources